EAM
DRUG

Eventide Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

Eventide Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.49M Buy
130,013
+27,000
+26% +$2.17M 0.16% 142
2025
Q4 		$8.04M Buy
+103,013
New +$6.88M 0.13% 152

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Eventide Asset Management's DRUG Position: Q1 2026 in Review

Eventide Asset Management increased its Bright Minds Biosciences (DRUG) stake by 26% in Q1 2026, buying an estimated $2.17M and bringing the position to 130,013 shares worth $9.49M. The position accounts for 0.16% of the portfolio, ranked #142.

Eventide Asset Management first reported a position in DRUG in Q4 2025 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Eventide Asset Management held 130,013 shares of Bright Minds Biosciences worth $9.49M as of Q1 2026.
  • Eventide Asset Management bought 27,000 Bright Minds Biosciences shares in Q1 2026, an estimated $2.17M.
  • Bright Minds Biosciences made up 0.16% of Eventide Asset Management's portfolio in Q1 2026, its #142 holding.
  • Eventide Asset Management first reported a position in Bright Minds Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Eventide Asset Management's 13F filing for Q1 2026, filed 15 May 2026.